A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
复制标题
CAG（阿糖胞苷、阿克拉霉素、G-CSF）方案治疗 1029 例急性髓系白血病和骨髓增生异常综合征患者的荟萃分析。
DOI：
10.1186/1756-8722-4-46
复制
发表时间：
2011-11-14
影响因子：
28.5
通讯作者：
Liu D
中科院分区：
文献类型：
--
作者：
Wei G;Ni W;Chiao JW;Cai Z;Huang H;Liu D
阿糖胞苷、阿糖胞苷、粒细胞集落刺激因子（CAG）方案在中国和日本已广泛应用于急性髓细胞白血病（AML）和骨髓增生异常综合征（MDS）的治疗。我们检索了1995年至2010年关于CAG的文献，并使用随机效应或固定效应模型进行了荟萃分析，以确定其总体疗效。共纳入了35项试验（共1029例AML（n = 814）和MDS（n = 215）患者）进行分析。AML的CR率（57.9%）明显高于MDS（45.7%）（P < 0.01）。新发（56.7%）和复发/难治性AML（60.1%）之间的CR无差异（p > 0.05）。染色体组型良好者（64.5%）和中间型者（69.6%）的CR率也明显高于染色体组型不良者（29.5%）（p < 0.05）。值得注意的是，CAG方案的CR率显著高于非CAG方案（比值比2.43）。CAG方案耐受性好，心脏毒性2.3%，早期死亡5.2%。结论：CAG方案治疗AML安全有效，可能优于非CAG方案。强烈建议进行随机对照试验，以评估其与当前标准治疗相比的有效性和安全性。
The regimen of cytarabine, aclarubicin and G-CSF (CAG) has been widely used in China and Japan for treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We searched literature on CAG between 1995 and 2010 and performed a meta-analysis to determine its overall efficacy using a random-effects or fixed-effects model. Thirty five trials with a total of 1029 AML (n = 814) and MDS (n = 215) patients were included for analysis. The CR rate of AML (57.9%) was significantly higher than that of MDS (45.7%) (p < 0.01). No difference in CR was noted between the new (56.7%) and relapsed/refractory AML (60.1%) (p > 0.05). The CR rate was also significantly higher in patients with favorable (64.5%) and intermediate (69.6%) karyotypes than those with unfavorable one (29.5%) (p < 0.05). Remarkably, the CR rate of CAG was significantly higher than those of non-CAG regimens (odds ratio 2.43). CAG regimen was well tolerated, with cardiotoxicity in 2.3% and early death in 5.2% of the cases. In conclusion, CAG regimen was an effective and safe regimen for the treatment of AML, and may be more effective than non-CAG regimens. Randomized controlled trials are strongly recommended to evaluate its efficacy and safety in comparison with the current standard treatment.
登录
查看更多内容
影响因子：
11.4
作者：
Estey, EH
通讯作者：
Estey, EH
影响因子：
28.5
作者：
Jiang S;Ma X;Huang Y;Xu Y;Zheng R;Chiao JW
通讯作者：
Chiao JW
DOI：
10.1016/j.mrgentox.2005.01.012
发表时间：
2005-05-02
影响因子：
1.9
作者：
Hajji, N;Mateos, S;Cortés, F
通讯作者：
Cortés, F
影响因子：
28.5
作者：
Gregory TK;Wald D;Chen Y;Vermaat JM;Xiong Y;Tse W
通讯作者：
Tse W
富含P-糖蛋白的人肝癌细胞对阿昔霉素敏感，并且对其他三种蒽环类细胞抗性。
影响因子：
8.8
作者：
Lehne, G;DeAngelis, P;Clausen, OPF;Rugstad, HE
通讯作者：
Rugstad, HE